Efficacy and safety of Adalimumab after failure of other anti-TNF α agents for plaque-type psoriasis: clinician behaviour in real life clinical practice.

CONCLUSION: Adalimumab profile was excellent in this 5-years retrospective observation, showing the clinical validity of interclass transitioning among anti-TNFα options.
PMID: 30273075 [PubMed - as supplied by publisher]

Source: Journal of Dermatological Treatment - October 3, 2018 Category: Dermatology Tags: J Dermatolog Treat Source Type: research